A review of creatine supplementation in age-related diseases: More than a supplement for athletes

F1000Research

Volumn 3, Issue , 2014, Pages

  Gonzales, Eric B ^a   Smith, Rachel N ^a   Agharkar, Amruta S ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CREATINE; RILUZOLE;

AGING; ALZHEIMER DISEASE; AMINO ACID TRANSPORT; AMYOTROPHIC LATERAL SCLEROSIS; ATHLETE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DECLARATIVE MEMORY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; EPISODIC MEMORY; HUMAN; HUNTINGTON CHOREA; LOADING DRUG DOSE; LONG TERM MEMORY; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT DURATION; WORKING MEMORY;

EID: 84923677243     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.5218.1     Document Type: Review

References (133)

1. Zeisel SH: Regulation of "nutraceuticals?. Science. 1999;285(5435):1853-1855. 10515789 10.1126/science.285.5435.1853
2. Schnirring L: Creatine supplements face scrutiny: Will users pay later? Phys Sports Med. 1998;26:15-23.
3. Bloch K Schoenheimer R: The Biological Precursors Of Creatine. J Biol Chem. 1941;138(1):167-194. Reference Source
4. Tarnopolsky MA Beal MF: Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol. 2001;49(5):561-574. 11357946 10.1002/ana.1028
5. Adhihetty PJ Beal MF: Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med. 2008;10(4):275-290. 19005780 10.1007/s12017-008-8053-y 2886719
6. Christie DL: Functional insights into the creatine transporter. In: Gajja S. Salomons, M Wyss, ed. Creatine and creatine kinase in health and disease. Netherlands: Springer;2007; 46:99-118. 10.1007/978-1-4020-6486-9_6
7. Lowe MT Faull RL Christie DL: The distribution of the creatine transporter throughout the human brain reveals a spectrum of creatine transporter immunoreactivity. J Comp Neurol. 2014. 25159005 10.1002/cne.23667
8. Walker JB: Creatine: biosynthesis, regulation, and function. Adv Enzymol Relat Areas Mol Biol. 1979;50:177-242. 386719 10.1002/9780470122952.ch4
9. Adhihetty PJ Irrcher I Joseph AM: Plasticity of skeletal muscle mitochondria in response to contractile activity. Exp Physiol. 2003;88(1):99-107. 12525859 10.1113/eph8802505
10. Wallimann T Wyss M Brdiczka D: Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J. 1992;281(Pt 1):21-40. 1731757 1130636
11. Peng TI Greenamyre JT: Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors. Mol Pharmacol. 1998;53(6):974-980. 9614198
12. Green DR Reed JC: Mitochondria and apoptosis. Science. 1998;281(5381):1309-1312. 9721092 10.1126/science.281.5381.1309
13. Steeghs K Benders A Oerlemans F: Altered Ca2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies. Cell. 1997;89(1):93-103. 9094718 10.1016/S0092-8674(00)80186-5
14. Wyss M Braissant O Pischel I: Creatine and creatine kinase in health and disease--a bright future ahead? Subcell Biochem. 2007;46:309-334. 18652084 10.1007/978-1-4020-6486-9_16
15. Xu CJ Klunk WE Kanfer JN: Phosphocreatine-dependent glutamate uptake by synaptic vesicles. A comparison with atp-dependent glutamate uptake. J Biol Chem. 1996;271(23):13435-13440. 8662761 10.1074/jbc.271.23.13435
16. Lawler JM Barnes WS Wu G: Direct antioxidant properties of creatine. Biochem Biophys Res Commun. 2002;290(1):47-52. 11779131 10.1006/bbrc.2001.6164
17. Dedeoglu A Kubilus JK Yang L: Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem. 2003;85(6):1359-1367. 12787055 10.1046/j.1471-4159.2003.01706.x 2866522
18. Araujo MB Moura LP Junior RC: Creatine supplementation and oxidative stress in rat liver. J Int Soc Sports Nutr. 2013;10(1):54. 24325803 10.1186/1550-2783-10-54 4029397
19. de Andrade RB Gemelli T Rojas DB: Creatine and Pyruvate Prevent the Alterations Caused by Tyrosine on Parameters of Oxidative Stress and Enzyme Activities of Phosphoryltransfer Network in Cerebral Cortex of Wistar Rats. Mol Neurobiol. 2014. 24961569 10.1007/s12035-014-8791-9
20. Stefani GP Nunes RB Dornelles AZ: Effects of creatine supplementation associated with resistance training on oxidative stress in different tissues of rats. J Int Soc Sports Nutr. 2014;11(1):11. 24655435 10.1186/1550-2783-11-11 3994392
21. Chevreul ME: Sur une nouvelle substance contenue dans la chair de boeuf. Paris Mus Hist Nat N Ann. 1832;I:306-316.
22. Wyss M Kaddurah-Daouk R: Creatine and creatinine metabolism. Physiol Rev. 2000;80(3):1107-1213. 10893433
23. Harris RC Soderlund K Hultman E: Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci (Lond). 1992;83(3):367-374. 1327657
24. Green AL Simpson EJ Littlewood JJ: Carbohydrate ingestion augments creatine retention during creatine feeding in humans. Acta Physiol Scand. 1996;158(2):195-202. 8899067 10.1046/j.1365-201X.1996.528300000.x
25. Steenge GR Simpson EJ Greenhaff PL: Protein- and carbohydrate-induced augmentation of whole body creatine retention in humans. J Appl Physiol (1985). 2000;89(3):1165-1171. 10956365
26. Burke DG Chilibeck Pd Parise GA: The effect of alpha lipoic acid supplementation on resting muscle creatine during acute creatine loading. FASEB J. 2001;15(5):A814.
27. Greenwood M Kreider RB Almada AL: D-pinitol augments whole body creatine retention in man. J Exercise Physiol Online. 2001;4(4):41-47. Reference Source
28. Persky AM Brazeau GA: Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev. 2001;53(2):161-176. 11356982
29. Izquierdo M Ibanez J Gonzalez-Badillo JJ: Effects of creatine supplementation on muscle power, endurance, and sprint performance. Med Sci Sports Exerc. 2002;34(2):332-343. 11828245
30. Mujika I Padilla S Ibanez J: Creatine supplementation and sprint performance in soccer players. Med Sci Sports Exerc. 2000;32(2):518-525. 10694141 10.1097/00005768-200002000-00039
31. Becque MD Lochmann JD Melrose DR: Effects of oral creatine supplementation on muscular strength and body composition. Med Sci Sports Exerc. 2000;32(3):654-658. 10731009 10.1097/00005768-200003000-00016
32. Kreider RB Ferreira M Wilson M: Effects of creatine supplementation on body composition, strength, and sprint performance. Med Sci Sports Exerc. 1998;30(1):73-82. 9475647 10.1097/00005768-199801000-00011
33. Vandenberghe K Goris M Van Hecke P: Long-term creatine intake is beneficial to muscle performance during resistance training. J Appl Physiol (1985). 1997;83(6):2055-2063. 9390981
34. Volek JS Boetes M Bush JA: Response of testosterone and cortisol concentrations to high-intensity resistance exercise following creatine supplementation. J Strength Conditioning Res. 1997;11(3). Reference Source
35. Jacobs I Bleue S Goodman J: Creatine ingestion increases anaerobic capacity and maximum accumulated oxygen deficit. Can J Appl Physiol. 1997;22(3):231-243. 9189303 10.1139/h97-015
36. Dawson B Cutler M Moody A: Effects of oral creatine loading on single and repeated maximal short sprints. Aust J Sci Med Sport. 1995;27(3):56-61. 8599745
37. Meir R: Practical application of oral creatine supplementation in professional rugby league: A case study. Australian Strength and Conditioning Coach. 1995;3(3):6-10. Reference Source
38. Antonio J Ciccone V: The effects of pre versus post workout supplementation of creatine monohydrate on body composition and strength. J Int Soc Sports Nutr. 2013;10:36. 23919405 10.1186/1550-2783-10-36 3750511
39. de Salles Painelli V Alves VT Ugrinowitsch C: Creatine supplementation prevents acute strength loss induced by concurrent exercise. Eur J Appl Physiol. 2014;114(8):1749-1755. 24840857 10.1007/s00421-014-2903-0
40. Camic CL Housh TJ Zuniga JM: The effects of polyethylene glycosylated creatine supplementation on anaerobic performance measures and body composition. J Strength Cond Res. 2014;28(3):825-833. 23897021 10.1519/JSC.0b013e3182a361a5
41. Mesa JL Ruiz JR Gonzalez-Gross MM: Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Sports Med. 2002;32(14):903-944. 12427051 10.2165/00007256-200232140-00003
42. Persky AM Muller M Derendorf H: Single- and multiple-dose pharmacokinetics of oral creatine. J Clin Pharmacol. 2003;43(1):29-37. 12520625 10.1177/0091270002239703
43. Hall M Trojian TH: Creatine supplementation. Curr Sports Med Rep. 2013;12(4):240-244. 23851411 10.1249/JSR.0b013e31829cdff2
44. Anderson O: Creatine propels british athletes to olympic gold medals: Is creatine the one true ergogenic aid? Running Research News. 1993;9:1-5.
45. Greenhaff PL Casey A Short AH: Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. Clin Sci (Lond). 1993;84(5):565-571. 8504634
46. Wyss M Schulze A: Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease? Neuroscience. 2002;112(2):243-260. 12044443 10.1016/S0306-4522(02)00088-X
47. Genc G Okuyucu A Meydan BC: Effect of free creatine therapy on cisplatin-induced renal damage. Ren Fail. 2014;36(7):1108-1113. 24845105 10.3109/0886022X.2014.917576
48. Dickinson H Ellery S Ireland Z: Creatine supplementation during pregnancy: summary of experimental studies suggesting a treatment to improve fetal and neonatal morbidity and reduce mortality in high-risk human pregnancy. BMC Pregnancy Childbirth. 2014;14:150. 24766646 10.1186/1471-2393-14-150 4007139
49. Leader A Amital D Rubinow A: An open-label study adding creatine monohydrate to ongoing medical regimens in patients with the fibromyalgia syndrome. Ann N Y Acad Sci. 2009;1173:829-836. 19758235 10.1111/j.1749-6632.2009.04811.x
50. Kreider RB: Effects of creatine supplementation on performance and training adaptations. Mol Cell Biochem. 2003;244(1-2):89-94. 12701815 10.1007/978-1-4615-0247-0_13.
51. Candow DG Chilibeck PD Forbes SC: Creatine supplementation and aging musculoskeletal health. Endocrine. 2014;45(3):354-361. 24190049 10.1007/s12020-013-0070-4
52. Lang AE Lozano AM: Parkinson's disease. First of two parts. N Engl J Med. 1998;339(15):1044-1053. 9761807 10.1056/NEJM199810083391506
53. Beal MF: Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol. 1996;6(5):661-666. 8937831 10.1016/S0959-4388(96)80100-0
54. Thomas B Beal MF: Parkinson's disease. Hum Mol Genet. 2007;16(R2):R183-94. 10.1093/hmg/ddm159
55. Matthews RT Ferrante RJ Klivenyi P: Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999;157(1):142-149. 10222117 10.1006/exnr.1999.7049
56. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66(5):664-671. 16481597 10.1212/01.wnl.0000201252.57661.e1
57. Hass CJ Collins MA Juncos JL: Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabil Neural Repair. 2007;21(2):107-115. 17312085 10.1177/1545968306293449
58. Statement on the termination of NET-PD LS-1 study. NET-PD NIH Exploratory Trials in Parkinson's Disease Web site.2013. Reference Source
59. Walker FO: Huntington's disease. Lancet. 2007;369(9557):218-228. 17240289 10.1016/S0140-6736(07)60111-1
60. Strong TV Tagle DA Valdes JM: Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet. 1993;5(3):259-265. 8275091 10.1038/ng1193-259
61. Landwehrmeyer GB McNeil SM Dure LS 4th: Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals. Ann Neurol. 1995;37(2):218-230. 7847863 10.1002/ana.410370213
62. Sharp AH Loev SJ Schilling G: Widespread expression of Huntington's disease gene (IT15) protein product. Neuron. 1995;14(5):1065-1074. 7748554 10.1016/0896-6273(95)90345-3
63. Ferrante RJ Gutekunst CA Persichetti F: Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J Neurosci. 1997;17(9):3052-3063. 9096140
64. Ryu H Ferrante RJ: Emerging chemotherapeutic strategies for Huntington's disease. Expert Opin Emerg Drugs. 2005;10(2):345-363. 15934871 10.1517/14728214.10.2.345
65. Koroshetz WJ Jenkins BG Rosen BR: Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol. 1997;41(2):160-165. 9029064 10.1002/ana.410410206
66. Wallimann T Hemmer W: Creatine kinase in non-muscle tissues and cells. Mol Cell Biochem. 1994;133-134:193-220. 7808454 10.1007/BF01267955
67. O'Gorman E Beutner G Dolder M: The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett. 1997;414(2):253-257. 9315696 10.1016/S0014-5793(97)01045-4
68. Matthews RT Yang L Jenkins BG: Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci. 1998;18(1):156-163. 9412496
69. Ferrante RJ Andreassen OA Jenkins BG: Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci. 2000;20(12):4389-4397. 10844007
70. Brouillet E Jenkins BG Hyman BT: Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem. 1993;60(1):356-359. 8417157 10.1111/j.1471-4159.1993.tb05859.x
71. Beal MF Brouillet E Jenkins BG: Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci. 1993;13(10):4181-4192. 7692009
72. Schulz JB Beal MF: Neuroprotective effects of free radical scavengers and energy repletion in animal models of neurodegenerative disease. Ann N Y Acad Sci. 1995;765:100-10; discussion 116-8. 7486598 10.1111/j.1749-6632.1995.tb16565.x
73. Browne SE Ferrante RJ Beal MF: Oxidative stress in Huntington's disease. Brain Pathol. 1999;9(1):147-163. 9989457 10.1111/j.1750-3639.1999.tb00216.x
74. Grunewald T Beal MF: Bioenergetics in Huntington's disease. Ann N Y Acad Sci. 1999;893:203-213. 10672239 10.1111/j.1749-6632.1999.tb07827.x
75. Andreassen OA Dedeoglu A Ferrante RJ: Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis. 2001;8(3):479-491. 11447996 10.1006/nbdi.2001.0406
76. Hersch SM Gevorkian S Marder K: Creatine in huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology. 2006;66(2):250-252. 16434666 10.1212/01.wnl.0000194318.74946.b6
77. Kim J Amante DJ Moody JP: Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochim Biophys Acta. 2010;1802(7-8):673-681. 20460152 10.1016/j.bbadis.2010.05.001 2893277
78. Walton JN: Brain's diseases of the nervous system. 10th ed. New York: Oxford University Press,1993:443-449. Reference Source
79. Dementia and motoneurone disease. Lancet. 1990;335(8700):1250-1252. 10.1016/0140-6736(90)91308-W
80. Hervias I Beal MF Manfredi G: Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve. 2006;33(5):598-608. 16372325 10.1002/mus.20489
81. Dugdale DC Hoch DB Zieve D: Amyotrophic lateral sclerosis. A D A M Medical Encyclopedia. 2010.
82. Zoccolella S Beghi E Palagano G: Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern italy. Eur J Neurol. 2007;14(3):262-268. 17355545 10.1111/j.1468-1331.2006.01575.x
83. Phukan J Pender NP Hardiman O: Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6(11):994-1003. 17945153 10.1016/S1474-4422(07)70265-X
84. Strong M Rosenfeld J: Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(3):136-143. 13129799 10.1080/14660820310011250
85. Siklos L Engelhardt J Harati Y: Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol. 1996;39(2):203-216. 8967752 10.1002/ana.410390210
86. Carri MT Ferri A Battistoni A: Expression of a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca2+ concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Lett. 1997;414(2):365-368. 9315720 10.1016/S0014-5793(97)01051-X
87. Kasarskis EJ Berryman S Vanderleest JG: Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr. 1996;63(1):130-137. 8604660
88. Reaume AG Elliott JL Hoffman EK: Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet. 1996;13(1):43-47. 8673102 10.1038/ng0596-43
89. Bruijn LI Houseweart MK Kato S: Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281(5384):1851-1854. 9743498 10.1126/science.281.5384.1851
90. Klivenyi P Ferrante RJ Matthews RT: Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999;5(3):347-350. 10086395 10.1038/6568
91. Shefner JM Cudkowicz ME Schoenfeld D: A clinical trial of creatine in ALS. Neurology. 2004;63(9):1656-1661. 15534251 10.1212/01.WNL.0000142992.81995.F0
92. Groeneveld GJ Veldink JH van der Tweel I: A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53(4):437-445. 12666111 10.1002/ana.10554
93. Hedden T Gabrieli JD: Insights into the ageing mind: a view from cognitive neuroscience. Nat Rev Neurosci. 2004;5(2):87-96. 14735112 10.1038/nrn1323
94. Nilsson LG: Memory function in normal aging. Acta Neurol Scand Suppl. 2003;179:7-13. 12603244
95. Sappey-Marinier D Calabrese G Fein G: Effect of photic stimulation on human visual cortex lactate and phosphates using 1H and 31P magnetic resonance spectroscopy. J Cereb Blood Flow Metab. 1992;12(4):584-592. 1618937 10.1038/jcbfm.1992.82
96. Rango M Castelli A Scarlato G: Energetics of 3.5 s neural activation in humans: a 31P MR spectroscopy study. Magn Reson Med. 1997;38(6):878-883. 9402187
97. Rae C Digney AL McEwan SR: Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial. Proc Biol Sci. 2003;270(1529):2147-2150. 14561278 10.1098/rspb.2003.2492 1691485
98. Lyoo IK Kong SW Sung SM: Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate. Psychiatry Res. 2003;123(2):87-100. 12850248 10.1016/S0925-4927(03)00046-5
99. McMorris T Mielcarz G Harris RC: Creatine supplementation and cognitive performance in elderly individuals. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2007;14(5):517-528. 17828627 10.1080/13825580600788100
100. Tiraboschi P Hansen LA Thal LJ: The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology. 2004;62(11):1984-1989. 15184601 10.1212/01.WNL.0000129697.01779.0A
101. Pettegrew JW Panchalingam K Klunk WE: Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol Aging. 1994;15(1):117-132. 8159258 10.1016/0197-4580(94)90152-X
102. Shonk T Ross BD: Role of increased cerebral myo-inositol in the dementia of Down syndrome. Magn Reson Med. 1995;33(6):858-861. 7651126
103. Huang W Alexander GE Daly EM: High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study. Am J Psychiatry. 1999;156(12):1879-1886. 10588400
104. Brewer GJ Wallimann TW: Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J Neurochem. 2000;74(5):1968-1978. 10800940 10.1046/j.1471-4159.2000.0741968.x
105. Castegna A Aksenov M Thongboonkerd V: Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem. 2002;82(6):1524-1532. 12354300 10.1046/j.1471-4159.2002.01103.x
106. David S Shoemaker M Haley BE: Abnormal properties of creatine kinase in Alzheimer's disease brain: correlation of reduced enzyme activity and active site photolabeling with aberrant cytosol-membrane partitioning. Brain Res Mol Brain Res. 1998;54(2):276-287. 9555058 10.1016/S0169-328X(97)00343-4
107. Gallant M Rak M Szeghalmi A: Focally elevated creatine detected in amyloid precursor protein (APP) transgenic mice and Alzheimer disease brain tissue. J Biol Chem. 2006;281(1):5-8. 16267054 10.1074/jbc.C500244200
108. Tachikawa M Fukaya M Terasaki T: Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. Eur J Neurosci. 2004;20(1):144-160. 15245487 10.1111/j.1460-9568.2004.03478.x
109. Braissant O Henry H Villard AM: Creatine synthesis and transport during rat embryogenesis: spatiotemporal expression of AGAT, GAMT and CT1. BMC Dev Biol. 2005;5:9. 15918910 10.1186/1471-213X-5-9 1175845
110. Straumann N Wind A Leuenberger T: Effects of N-linked glycosylation on the creatine transporter. Biochem J. 2006;393(Pt 2):459-469. 16167890 10.1042/BJ20050857 1360696
111. Stachowiak O Dolder M Wallimann T: Mitochondrial creatine kinase is a prime target of peroxynitrite-induced modification and inactivation. J Biol Chem. 1998;273(27):16694-16699. 9642223 10.1074/jbc.273.27.16694
112. Stroke--1989. recommendations on stroke prevention, diagnosis, and therapy. report of the WHO task force on stroke and other cerebrovascular disorders. Stroke. 1989;20(10):1407-1431. 2799873 10.1161/01.STR.20.10.1407
113. World health organization: the top 10 causes of death.2014. Reference Source
114. Hickey JV: The clinical practice of neurological and neurosurgical nursing. 5th ed. Philadelphia: Lippincott, Williams & Wilkins,2003. Reference Source
115. Ingall T: Stroke--incidence, mortality, morbidity and risk. J Insur Med. 2004;36(2):143-152. 15301227
116. Warner DS Sheng H Batinic-Haberle I: Oxidants, antioxidants and the ischemic brain. J Exp Biol. 2004;207(Pt 18):3221-3231. 15299043 10.1242/jeb.01022
117. Wardlaw JM Murray V Berge E: Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009; (4):CD000213. 19821269 10.1002/14651858.CD000213.pub2
118. Richard MJ Saleh TM El Bahh B: A novel method for inducing focal ischemia in vitro. J Neurosci Methods. 2010;190(1):20-27. 20417233 10.1016/j.jneumeth.2010.04.017
119. Ye R Li N Han J: Neuroprotective effects of ginsenoside Rd against oxygen-glucose deprivation in cultured hippocampal neurons. Neurosci Res. 2009;64(3):306-310. 19447300 10.1016/j.neures.2009.03.016
120. Menzies SA Hoff JT Betz AL: Middle cerebral artery occlusion in rats: a neurological and pathological evaluation of a reproducible model. Neurosurgery. 1992;31(1):100-6; discussion 106-7. 1641086
121. Miyake K Takeo S Kaijihara H: Sustained decrease in brain regional blood flow after microsphere embolism in rats. Stroke. 1993;24(3):415-420. 8446979 10.1161/01.STR.24.3.415
122. Bacigaluppi M Comi G Hermann DM: Animal models of ischemic stroke. Part two: modeling cerebral ischemia. Open Neurol J. 2010;4:34-38. 20721320 10.2174/1874205X01004020034 2923341
123. Arsava EM Gurer G Gursoy-Ozdemir Y: A new model of transient focal cerebral ischemia for inducing selective neuronal necrosis. Brain Res Bull. 2009;78(4-5):226-231. 19063950 10.1016/j.brainresbull.2008.11.005
124. Gideon P Henriksen O Sperling B: Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study. Stroke. 1992;23(11):1566-1572. 1440704 10.1161/01.STR.23.11.1566
125. Carter AJ Muller RE Pschorn U: Preincubation with creatine enhances levels of creatine phosphate and prevents anoxic damage in rat hippocampal slices. J Neurochem. 1995;64(6):2691-2699. 7760049 10.1046/j.1471-4159.1995.64062691.x
126. Balestrino M Rebaudo R Lunardi G: Exogenous creatine delays anoxic depolarization and protects from hypoxic damage: dose-effect relationship. Brain Res. 1999;816(1):124-130. 9878706 10.1016/S0006-8993(98)01131-7
127. Sestili P Martinelli C Bravi G: Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med. 2006;40(5):837-849. 16520236 10.1016/j.freeradbiomed.2005.10.035
128. Wilken B Ramirez JM Probst I: Anoxic ATP depletion in neonatal mice brainstem is prevented by creatine supplementation. Arch Dis Child Fetal Neonatal Ed. 2000;82(3):F224-7. 10794791 10.1136/fn.82.3.F224 1721092
129. Otellin VA Korzhevskii DE Kostkin VB: The neuroprotective effect of creatine in rats with cerebral ischemia. Dokl Biol Sci. 2003;390:197-199. 12940139 10.1023/A:1024432911738
130. Lensman M Korzhevskii DE Mourovets VO: Intracerebroventricular administration of creatine protects against damage by global cerebral ischemia in rat. Brain Res. 2006;1114(1):187-194. 16949559 10.1016/j.brainres.2006.06.103
131. Adcock KH Nedelcu J Loenneker T: Neuroprotection of creatine supplementation in neonatal rats with transient cerebral hypoxia-ischemia. Dev Neurosci. 2002;24(5):382-388. 12640176 10.1159/000069043
132. Zhu S Li M Figueroa BE: Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J Neurosci. 2004;24(26):5909-5912. 15229238 10.1523/JNEUROSCI.1278-04.2004
133. Perasso L Spallarossa P Gandolfo C: Therapeutic use of creatine in brain or heart ischemia: available data and future perspectives. Med Res Rev. 2013;33(2):336-363. 22135003 10.1002/med.20255